Brief: Vistagen And Fuji Enter Exclusive Negotiation Agreement For A Potential License To Develop And Commercialize Vistagen’S Investigational Menopausal Hot Flash Therapy, Ph80 Nasal Spray, In Japan
05/09/2023 14:02
Fuji Pharma Co Ltd 4554.T :
* VISTAGEN AND FUJI ENTER EXCLUSIVE NEGOTIATION AGREEMENT
FOR A
POTENTIAL LICENSE TO DEVELOP AND COMMERCIALIZE VISTAGEN’S
INVESTIGATIONAL MENOPAUSAL HOT FLASH THERAPY, PH80 NASAL SPRAY,
IN JAPAN
* VISTAGEN THERAPEUTICS INC- VISTAGEN TO RECEIVE $1.5
MILLION AND
FUJI TO OBTAIN TIME-LIMITED EXCLUSIVE NEGOTIATION PERIOD FOR
JAPANESE MARKET
Source text for Eikon: ID:nBw3dQdqLa
Further company coverage: 4554.T
Recent news on Vistagen Therapeutics
See all newsBrief: Vistagen TherapeuticsSays Fasedienol Nasal Spray Well-Tolerated With No New Drug-Related Safety Findings After 12 Months
VistaGen Q1 revenue rises on licensing agreement expiration
Brief: VistaGen Q1 EPS USD -0.3
Vistagen Therapeutics Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Vistagen Appoints Douglas J. Williamson To Its Board Of Directors